Pfizer has announced that clinical trials of Exubera resulted in increased cases of lung cancer. Lewis Krauskopf of Reuters is on it:
Pfizer Inc and Nektar Therapeutics said on Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to stop seeking a marketing partner for the troubled product and abandon it.Scary, but not that surprising, because—good or bad—Dr. Fuhrman insists all drugs futz with the normal functioning of the body:
Nektar shares tumbled 25 percent, while shares of MannKind Corp, which has been developing its own inhaled insulin, plummeted 58 percent. Pfizer was down slightly at $20.90.
The lung-cancer revelation dealt a final setback to Exubera, which held the promise of letting diabetics avoid needle sticks and was once projected by Pfizer to be a $2 billion-a-year blockbuster. Instead, Exubera has been a commercial flop that has sullied the inhaled insulin field.
In the first pharmacology lecture that I head in medical school, the physician impressed on us that all drugs are toxic and we should never forget this. We were taught that medications work because of their pharmacologic properties—properties that enable the substance to interfere with, block, or stimulate an activity of the body. Drugs typically modify the way the body expresses the signs and symptoms of disease, but in chronic disease states, they do no undo the damage or remove the disease.My suspicion is this concept often more often than not, takes a backseat to the pursuit of profits and convenience.